CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2025

Nov 25, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2025-11-20

Reporting Person: Daly Richard J (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-21	Common Stock, par value $0.001 per share	M	20006	—	Acquired	246800	Direct
2025-11-21	Common Stock, par value $0.001 per share	F	7872	—	Disposed	238928	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-20	Options to purchase common stock	$22.77	A	381948	Acquired	2032-11-20	Common Stock (381948)	Direct
2025-11-20	Restricted Stock Units	$	A	115283	Acquired		Common Stock (115283)	Direct
2025-11-21	Restricted Stock Units	$	M	20006	Disposed		Common Stock (20006)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.

F3: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.

F4: Shares of common stock will be delivered to the Reporting Person upon vesting.

F5: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.

F6: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.